Elan Divests Alzheimer Unit

Davis, Avram
July 2009
Mergers & Acquisitions Report;7/27/2009, Vol. 22 Issue 30, p4
The article reveals the plan of the pharmaceutical manufacturer Elan Corporation plc to divest its Alzheimer's immunotherapy program to Johnson & Johnson. The sale of Elan's its Alzheimer immunotherapy program to the healthcare company marks the result of a strategic review announced by Elan, in which it hired Citigroup Global Markets to assist in examining its options. The financial results of Elan for the second quarter are noted.


Related Articles

  • J&J Deal Lifts Overhang on Elan Stock; Investors Cautious. Sheridan, Cormac // BioWorld International;7/8/2009, Vol. 14 Issue 27, p1 

    The article reports on the U.S.$1.5 billion partnership deal signed by Elan Corp. PLC with Johnson & Johnson covering its Alzheimer's disease immunotherapy program. The growth of Elan's drug was hampered by reports of progressive multifocal leukoencephalopathy (PML) occuring in multiple...

  • Elan to Sell Its Alzheimer's Immunotherapy Proqram to J&J.  // Chain Drug Review;7/20/2009, Vol. 31 Issue 12, p104 

    The article reports on the acquisition of the assets and rights of Elan Corp. PLC's Alzheimer's immunotherapy program by Johnson & Johnson (J&J) in New Brunswick, New Jersey. It mentions that the move manifests the firm's interest to collaborate with Wyeth in commercializing, developing and...

  • The Industry.  // Pharmaceutical Representative;Aug2009, Vol. 39 Issue 8, p7 

    The article offers world news briefs related to the pharmaceutical industry. Wyeth and Catalyst Biosciences Inc. will partner on the discovery, development and commercialization of Factor Vlla products to treat bleeding conditions and treat hemophilia. Johnson & Johnson will acquire the assets...

  • J&J acquires $1B stake in Elan; Interleukin sells unit to Pep.  // Medical Device Daily;7/6/2009, Vol. 13 Issue 127, p5 

    The article reports on the acquisition of Johnson & Johnson (J&J) of the assets and rights of Elan involved in its Alzheimer's Immunotherapy Program (AIP). It furthers that J&J will spend $1 billion in exchange for newly issued American depositary receipts (ADRs) of Elan, forming 18.4% of Elan's...

  • Elan's AD Drug Down, Not Out: J&J Pledges $1.5B in Venture. Hollingsworth, Catherine // BioWorld International;7/8/2009, Vol. 14 Issue 27, p3 

    The article reports on the plan of Johnson & Johnson to invest a total of $1.5 billion in Elan Corp. PLC. In return, the company will transfer its Alzheimer's programs. According to Johnson & Johnson's Srikant Ramaswami, the deal is important as it presented the deal as an opportunity to...

  • Elan's AD Drug Down, Not Out: J&J Pledges $1.5B in Venture. Hollingsworth, Catherine // BioWorld Today;7/6/2009, Vol. 20 Issue 127, p1 

    The article reports on the plan of U.S. drugmaker Johnson & Johnson (J&J) to make a $1.5 billion investment in Elan Corp. PLC in Dublin, Ireland, in exchange for a stake in the company. According to J&J spokesman Srikant Ramaswami, the deal represents an opportunity for the company to build a...

  • AD Attracts Huge Interest Despite Failures. Powers, Marie // BioWorld Today;8/27/2012, Vol. 23 Issue 166, p5 

    The article reports on the interest of several companies in developing drugs that could cure Alzheimer's disease despite failures in clinical trials, such as Johnson & Johnson, Pfizer Inc. and Elan Corp. PLC's bapineuzumab. Satori Pharmaceuticals is developing a class of oral gamma-secretase...

  • J&J-Pfizer's Alzheimer's Drug Crashes, Burns in Phase III. Sheridan, Cormac // BioWorld International;8/8/2012, Vol. 17 Issue 32, p1 

    The article reports on the failure of Pfizer Inc. and Johnson and Johnson's bapineuzumab to pass the Phase III trial in Alzheimer's disease. It notes that the antibody, which is discovered and developed by Elan Corp. PLC, has failed to meet the co-primary cognitive and functional performance...

  • Untitled.  // MondayMorning;3/8/2010, Vol. 18 Issue 9, p20 

    The article focuses on new imaging technology which suggests an experimental drug for Alzheimer's disease. First drug which would treat the degenerative brain disease has been developed by the biotech companies including Pfizer Inc., Elan Corp Plc and Johnson & Johnson. It informs that the drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics